Phoenix Financial’s NovoCure NVCR Stock Holding History

Phoenix Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,123	Closed	-$554K	–	326
2022 Q3	$554K	Sell	7,123 -19,495	-73%	-$1.52M	0.01%	242
2022 Q2	$1.87M	Sell	26,618 -9,003	-25%	-$678K	0.04%	172
2022 Q1	$2.96M	Sell	35,621 -3,858	-10%	-$284K	0.05%	161
2021 Q4	$3.04M	Buy	39,479 +1	+0%	+$100	0.05%	158
2021 Q3	$4.58M	Buy	39,478 +1,361	+4%	+$206K	0.08%	144
2021 Q2	$8.49M	Sell	38,117 -2,661	-7%	-$518K	0.16%	116
2021 Q1	$5.22M	Sell	40,778 -85,745	-68%	-$13.6M	0.12%	144
2020 Q4	$21.9M	Sell	126,523 -71,448	-36%	-$9.78M	0.59%	65
2020 Q3	$20.4M	Buy	197,971 +15,520	+9%	+$1.24M	0.85%	42
2020 Q2	$10.2M	Buy	182,451 +33,734	+23%	+$2.22M	0.43%	73
2020 Q1	$9.72M	Buy	148,717 +112,046	+306%	+$8.85M	0.49%	67
2019 Q4	$3.07M	Sell	36,671 -239	-0.6%	-$19.3K	0.13%	121
2019 Q3	$2.63M	Buy	+36,910	New	+$2.95M	0.12%	120

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Phoenix Financial's NVCR Position: Q4 2022 in Review

Phoenix Financial sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 7,123 shares — an estimated $554K sold.

Phoenix Financial first reported a position in NVCR in Q3 2019 and held it in 13 quarters. The position peaked at $21.9M in Q4 2020. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

Phoenix Financial reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
Phoenix Financial sold 7,123 NovoCure shares in Q4 2022, an estimated $554K.
Phoenix Financial first reported a position in NovoCure in Q3 2019 and held it in 13 quarters.
Phoenix Financial's NovoCure position peaked at $21.9M in Q4 2020.
304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Phoenix Financial's 13F filing for Q4 2022, filed 13 Feb 2023.